Sciact
  • EN
  • RU

The main protease 3CLpro of the SARS-CoV-2 virus: how to turn an enemy into a helper Научная публикация

Журнал Frontiers in Bioengineering and Biotechnology
ISSN: 2296-4185
Вых. Данные Год: 2023, Том: 11, Страницы: 10.3389/fbioe.2023.1187761 Страниц : DOI: 10.3389/fbioe.2023.1187761
Ключевые слова E. coli bacteria, 3CL protease, TEV protease, RBD, SARS-CoV-2
Авторы Belenkaya Svetlana V. 1,2,3 , Merkuleva Iuliia A. 2 , Yarovaya Olga I. 1,3 , Chirkova Varvara Yu. 4 , Sharlaeva Elena A. 4 , Shanshin Daniil V. 2 , Volosnikova Ekaterina A. 2 , Vatsadze Sergey Z. 5 , Khvostov Mikhail V. 3 , Salakhutdinov Nariman F. 3 , Shcherbakov Dmitriy N. 2,3,4
Организации
1 Laboratory of Bionanotechnology, Microbiology and Virology, Novosibirsk State University, Novosibirsk, Russia
2 State Research Center of Virology and Biotechnology VECTOR, Koltsovo, Russia
3 Department of Medicinal Chemistry, N.N Vorozhtsov Novosibirsk Institute of Organic Chemistry SB RAS, Novosibirsk, Russia
4 Department of Physical-Chemistry Biology and Biotechnology, Altay State University, Barnaul, Russia
5 N.D Zelinsky Institute of Organic Chemistry, Russian Academy of Sciences, Moscow, Russia

Реферат: Despite the long history of use and the knowledge of the genetics and biochemistry of E. coli, problems are still possible in obtaining a soluble form of recombinant proteins in this system. Although, soluble protein can be obtained both in the cytoplasm and in the periplasm of the bacterial cell. The latter is a priority strategy for obtaining soluble proteins. The fusion protein technology followed by detachment of the fusion protein with proteases is used to transfer the target protein into the periplasmic space of E. coli. We have continued for the first time to use the main viral protease 3CL of the SARS-CoV-2 virus for this purpose. We obtained a recombinant 3CL protease and studied its complex catalytic properties. The authenticity of the resulting recombinant enzyme, were confirmed by specific activity analysis and activity suppression by the known low-molecular-weight inhibitors. The catalytic efficiency of 3CL (0.17 ± 0.02 µM-1-s-1) was shown to be one order of magnitude higher than that of the widely used tobacco etch virus protease (0.013 ± 0.003 µM-1-s-1). The application of the 3CL gene in genetically engineered constructs provided efficient specific proteolysis of fusion proteins, which we demonstrated using the receptor-binding domain of SARS-CoV-2 spike protein and GST fusion protein. The solubility and immunochemical properties of RBD were preserved. It is very important that in work we have shown that 3CL protease works effectively directly in E. coli cells when co-expressed with the target fusion protein, as well as when expressed as part of a chimeric protein containing the target protein, fusion partner, and 3CL itself. The results obtained in the work allow expanding the repertoire of specific proteases for researchers and biotechnologists.
Библиографическая ссылка: Belenkaya S.V. , Merkuleva I.A. , Yarovaya O.I. , Chirkova V.Y. , Sharlaeva E.A. , Shanshin D.V. , Volosnikova E.A. , Vatsadze S.Z. , Khvostov M.V. , Salakhutdinov N.F. , Shcherbakov D.N.
The main protease 3CLpro of the SARS-CoV-2 virus: how to turn an enemy into a helper
Frontiers in Bioengineering and Biotechnology. 2023. V.11. P.10.3389/fbioe.2023.1187761. DOI: 10.3389/fbioe.2023.1187761 WOS Scopus РИНЦ OpenAlex
Даты:
Поступила в редакцию: 16 мар. 2023 г.
Принята к публикации: 21 июн. 2023 г.
Опубликована online: 29 июн. 2023 г.
Идентификаторы БД:
Web of science: WOS:001029481300001
Scopus: 2-s2.0-85165039447
РИНЦ: 62030309
OpenAlex: W4382775048
Цитирование в БД:
БД Цитирований
OpenAlex 3
Web of science 3
Альметрики: